KR100645143B1 - 항혈전제와 아스피린의 결합체 및 이의 죽상혈전성 질환을치료하기 위한 용도 - Google Patents

항혈전제와 아스피린의 결합체 및 이의 죽상혈전성 질환을치료하기 위한 용도 Download PDF

Info

Publication number
KR100645143B1
KR100645143B1 KR1020047015845A KR20047015845A KR100645143B1 KR 100645143 B1 KR100645143 B1 KR 100645143B1 KR 1020047015845 A KR1020047015845 A KR 1020047015845A KR 20047015845 A KR20047015845 A KR 20047015845A KR 100645143 B1 KR100645143 B1 KR 100645143B1
Authority
KR
South Korea
Prior art keywords
aspirin
compound
pharmaceutical composition
combination
antithrombotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020047015845A
Other languages
English (en)
Korean (ko)
Other versions
KR20040098053A (ko
Inventor
또니 베르뵈랭
질베르 라비엘르
베르나르 씨메띠르
마리-오딜르 발레
Original Assignee
르 라보레또레 쎄르비에르
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 르 라보레또레 쎄르비에르 filed Critical 르 라보레또레 쎄르비에르
Publication of KR20040098053A publication Critical patent/KR20040098053A/ko
Application granted granted Critical
Publication of KR100645143B1 publication Critical patent/KR100645143B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020047015845A 2002-04-05 2003-04-04 항혈전제와 아스피린의 결합체 및 이의 죽상혈전성 질환을치료하기 위한 용도 Expired - Fee Related KR100645143B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0204222A FR2838057B1 (fr) 2002-04-05 2002-04-05 Nouvelle association d'un antithrombotique et d'aspirine
FR02/04222 2002-04-05
PCT/FR2003/001054 WO2003084525A1 (fr) 2002-04-05 2003-04-04 Nouvelle association d'un antithrombotique et d'aspirine

Publications (2)

Publication Number Publication Date
KR20040098053A KR20040098053A (ko) 2004-11-18
KR100645143B1 true KR100645143B1 (ko) 2006-11-10

Family

ID=28052120

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047015845A Expired - Fee Related KR100645143B1 (ko) 2002-04-05 2003-04-04 항혈전제와 아스피린의 결합체 및 이의 죽상혈전성 질환을치료하기 위한 용도

Country Status (26)

Country Link
US (1) US7618955B2 (enExample)
EP (1) EP1496884B1 (enExample)
JP (1) JP4065853B2 (enExample)
KR (1) KR100645143B1 (enExample)
CN (1) CN1297265C (enExample)
AR (1) AR039253A1 (enExample)
AT (1) ATE329591T1 (enExample)
AU (1) AU2003246774B2 (enExample)
BR (1) BR0309019A (enExample)
CA (1) CA2480697A1 (enExample)
CY (1) CY1105106T1 (enExample)
DE (1) DE60306133T2 (enExample)
DK (1) DK1496884T3 (enExample)
EA (1) EA006978B1 (enExample)
ES (1) ES2264533T3 (enExample)
FR (1) FR2838057B1 (enExample)
GE (1) GEP20074101B (enExample)
MA (1) MA27114A1 (enExample)
MX (1) MXPA04009760A (enExample)
NO (1) NO20044700L (enExample)
NZ (1) NZ535430A (enExample)
PL (1) PL371620A1 (enExample)
PT (1) PT1496884E (enExample)
UA (1) UA79457C2 (enExample)
WO (1) WO2003084525A1 (enExample)
ZA (1) ZA200407593B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMP200800012B (it) * 2005-07-22 2008-02-27 Procter & Gamble Composizioni per ridurre l'incidenza di aritmia indotta da farmaco
CN103071154A (zh) 2007-04-13 2013-05-01 千年药品公司 用起因子xa抑制剂作用的化合物的组合抗凝治疗
JP2009001537A (ja) * 2007-06-25 2009-01-08 Lab Servier 血管障害の処置を目的とする医薬の入手における抗アテローム血栓化合物の使用
FR2920772B1 (fr) * 2007-09-11 2009-10-23 Servier Lab Association entre un anti-atherothrombotique et un inhibiteur de l'enzyme de conversion de l'angiotensine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2711139B1 (fr) * 1993-10-15 1995-12-01 Adir Nouveaux dérivés de 1,2,3,4-tétrahydronaphtalène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.

Also Published As

Publication number Publication date
US7618955B2 (en) 2009-11-17
UA79457C2 (en) 2007-06-25
EP1496884A1 (fr) 2005-01-19
NZ535430A (en) 2006-09-29
CN1297265C (zh) 2007-01-31
FR2838057A1 (fr) 2003-10-10
BR0309019A (pt) 2005-02-01
FR2838057B1 (fr) 2005-07-08
MA27114A1 (fr) 2004-12-20
DK1496884T3 (da) 2006-10-02
EA006978B1 (ru) 2006-06-30
ATE329591T1 (de) 2006-07-15
CY1105106T1 (el) 2009-11-04
PL371620A1 (en) 2005-06-27
ES2264533T3 (es) 2007-01-01
EP1496884B1 (fr) 2006-06-14
EA200401293A1 (ru) 2005-02-24
AU2003246774A1 (en) 2003-10-20
MXPA04009760A (es) 2004-12-13
AR039253A1 (es) 2005-02-16
GEP20074101B (en) 2007-05-10
NO20044700L (no) 2004-10-29
HK1076034A1 (en) 2006-01-06
WO2003084525A1 (fr) 2003-10-16
ZA200407593B (en) 2006-07-26
AU2003246774B2 (en) 2007-02-15
PT1496884E (pt) 2006-09-29
JP2005528376A (ja) 2005-09-22
DE60306133T2 (de) 2007-01-04
US20050143354A1 (en) 2005-06-30
KR20040098053A (ko) 2004-11-18
DE60306133D1 (de) 2006-07-27
CN1646111A (zh) 2005-07-27
CA2480697A1 (fr) 2003-10-16
JP4065853B2 (ja) 2008-03-26

Similar Documents

Publication Publication Date Title
TW202237087A (zh) 作為醫藥活性化合物之大麻素衍生物及其製備方法
KR100645143B1 (ko) 항혈전제와 아스피린의 결합체 및 이의 죽상혈전성 질환을치료하기 위한 용도
TW200303214A (en) Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
Sabbatini et al. Nicardipine and treatment of cerebrovascular diseases with particular reference to hypertension-related disorders
JP2012532855A (ja) 医薬として使用するための組合せ製剤
KR100329254B1 (ko) 순환장해개선제
JP2004517947A (ja) そう痒状態の処置のためのｍｇｌｕｒ５アンタゴニストの使用
JP2005528376A5 (enExample)
KR100782246B1 (ko) 항혈전제와 항혈소판 응집제의 조합체
JP2000103736A (ja) 血管透過性亢進抑制剤
JP5198852B2 (ja) 脳梗塞に関連する脳血管障害の治療に有用なピラゾロン化合物
HK1076034B (en) Novel association of an antithrombotic agent with aspirin and use thereof for the manufacture of a medicament for treating atherothrombotic diseases
ES2322538T3 (es) Inhibidores contra el aumento de la tension ocular causada por irradiacion con laseres, que contienen derivados de 1,4-dihidropiridina.
JP2010195759A (ja) １，４−ベンゾチアゼピン誘導体並びにその製造方法及びその用途
KR101167036B1 (ko) 신경 보호 효과에 탁월한 신규한 물질로 할로알킬 살리실 산 유도체와 이의 약학적으로 허용 가능한 염 및 이를 유효 성분으로 함유하는 뇌질환의 치료 및 예방용 약제학적 조성물
JPS61172820A (ja) カルシウム拮抗剤
JPH0524134B2 (enExample)
HK1093900B (en) Novel association consisting of an anti-atherothrombotic agent and of a platelet antiaggregating agent
JPH0811730B2 (ja) 循環改善剤
WO2001012194A1 (fr) ASSOCIATIONS A ACTIVITE ANTI-THROMBOTIQUE CONSTITUEES DE L'HYDROGENOSULFATE DE CLOPIDOGREL ET D'UN ANTAGONISTE DES RECEPTEURS GPIIb/IIIa
JPWO1996011180A1 (ja) 血小板凝集阻害作用を有するγ−ジケトン化合物

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20090921

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20101104

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20101104